Patents by Inventor Piaoyang Sun

Piaoyang Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10905743
    Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: February 2, 2021
    Inventors: Xiangdong Qu, Xin Ye, Qiyue Hu, Dongbing Cui, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Publication number: 20210000954
    Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further con a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, obtaining a stable injected pharmaceutical preparation.
    Type: Application
    Filed: September 2, 2020
    Publication date: January 7, 2021
    Inventors: Jie Li, Zhen Yan, Pingping Wang, Yan Fang, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Publication number: 20200399375
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: August 7, 2020
    Publication date: December 24, 2020
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Patent number: 10857146
    Abstract: A method for preventing or treating tumor diseases with a combination of a tyrosine kinase inhibitor and a CDK4/6 inhibitor is provided. In particular, a method for preventing or treating tumor diseases, including administering to a patient a tyrosine kinase inhibitor of a compound of formula (I), or a complex, a pharmaceutically acceptable salt or a stereoisomer thereof and a CDK4/6 inhibitor is provided.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: December 8, 2020
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Jiahua Jiang, Cheng Liao, Lianshan Zhang, Piaoyang Sun, Lin Shen, Jing Gao, Jifang Gong
  • Patent number: 10815304
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 27, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • Patent number: 10793643
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 6, 2020
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Shaoyu Xu, Bei Yuan, Dongbing Cui, Qiyue Hu, Lei Zhang, Zhibin Xu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Patent number: 10786567
    Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 29, 2020
    Assignees: Suzhou Suncediabiopharmaeuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jie Li, Zhen Yan, Pingping Wang, Yan Fang, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Patent number: 10759788
    Abstract: Pharmaceutical uses of pyridinecarboxamide derivatives are provided. In particular, pharmaceutical uses of pyridinecarboxamide derivatives represented by general formula (I), wherein the substituents of the formula (I) are defined in the specification, are provided. The pyridinecarboxamide derivatives can be used as therapeutic agents, especially as inhibitors of the Renal Outer Medullary Potassium channel (ROMK) and in the preparation of medicaments for treating and/or preventing ROMK mediated disorders, such as hypertension and heart failure.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 1, 2020
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Xin Li, Qing Dong, Piaoyang Sun
  • Publication number: 20200270365
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and medical uses thereof.
    Type: Application
    Filed: December 26, 2016
    Publication date: August 27, 2020
    Inventors: Xiangdong QU, Xin YE, Houcong JIN, Dongbing CUI, Qiyue HU, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • Patent number: 10633388
    Abstract: Pyrazolopyrimidone derivatives and methods of use thereof are described. Specifically, pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: April 28, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., ltd., Jiangsu Hangrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Bin Gui, Qing Dong
  • Publication number: 20200061049
    Abstract: A method for preventing or treating tumor diseases with a combination of a tyrosine kinase inhibitor and a CDK4/6 inhibitor is provided. In particular, a method for preventing or treating tumor diseases, including administering to a patient a tyrosine kinase inhibitor of a compound of formula (I), or a complex, a pharmaceutically acceptable salt or a stereoisomer thereof and a CDK4/6 inhibitor is provided.
    Type: Application
    Filed: August 20, 2019
    Publication date: February 27, 2020
    Inventors: Jiahua Jiang, Cheng Liao, Lianshan Zhang, Piaoyang Sun, Lin Shen, Jing Gao, Jifang Gong
  • Publication number: 20200030453
    Abstract: A method for preparing an antibody-drug conjugate (ADC). In particular, the method mainly utilizes a combination of antibody biomolecules and an ion exchange carrier through electrostatic interaction to realize solid phase preparation of an ADC drug. Elution conditions are optimized, to control a drug-to-antibody coupling ratio (DAR) and separate a polymer-coupled drug, reduce the amount of a drug used in a coupling reaction, and enhance the targeted therapeutic effect of an ADC drug. The preparation method features fewer steps, simple operation, and programmable control, facilitating industrial scale-up production, and also realizing zero retention of reducing agents and organic solvents in the preparation process, significantly improving drug safety and reducing production costs.
    Type: Application
    Filed: March 29, 2018
    Publication date: January 30, 2020
    Inventors: Yupeng Liu, Xiaofei Zhang, Zhi Liang, Ruijun Shi, Jin Zhong, Xun Liu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Publication number: 20190315886
    Abstract: Provided are a thrombin antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a chimeric antibody and a humanized antibody comprising a thrombin antibody CDR region, and a pharmaceutical composition comprising the thrombin antibody and the antigen-binding fragment thereof, as well as the use thereof as an anticoagulant drug. In particular, provided is a use of the humanized thrombin antibody in preparing a drug for treating a thrombin-mediated disease or condition.
    Type: Application
    Filed: February 3, 2017
    Publication date: October 17, 2019
    Inventors: Hua YING, Jiajian LIU, Yayuan FU, Ling ZHANG, Haoying ZHANG, Jiakang SUN, Lianshan ZHANG, Weikang TAO, Piaoyang SUN, Qiyue HU
  • Patent number: 10442793
    Abstract: The present invention relates to an oxa spiro derivative, a preparation method therefor, and applications thereof in medicines. Particularly, the present invention relates to an oxa spiro derivative represented by formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative, applications thereof as an MOR receptor agonist, and applications in the preparation of drugs for treating and/or preventing pains and pains-related diseases. Substituent groups in the formula (I) are same as definitions in the specification.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 15, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Binqiang Feng, Yang Chen, Tao Liu, Feng He, Mingxun He, Weikang Tao, Piaoyang Sun
  • Patent number: 10442794
    Abstract: Processes for preparing pyridinecarboxamide derivatives are provided. In particular, process for preparing pyridinecarboxamide derivatives represented by general formula (I) are provided, wherein the substituents of the formula (I) are defined in the specification.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 15, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Qing Dong, Piaoyang Sun
  • Publication number: 20190275021
    Abstract: A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.
    Type: Application
    Filed: November 30, 2017
    Publication date: September 12, 2019
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Jiahua JIANG, Guoqing CAO, Changyong YANG, Lianshan ZHANG, Jianjun ZOU, Piaoyang SUN
  • Publication number: 20190270748
    Abstract: Pyrazolopyrimidone derivatives and methods of use thereof are described. Specifically, pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
    Type: Application
    Filed: May 20, 2019
    Publication date: September 5, 2019
    Inventors: Hejun LU, Piaoyang SUN, Bin GUI, Qing DONG
  • Patent number: 10398689
    Abstract: The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: September 3, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Chunfei Wang, Mingxun He, Qiyue Hu, Feng He, Weikang Tao, Piaoyang Sun
  • Publication number: 20190233513
    Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.
    Type: Application
    Filed: June 22, 2017
    Publication date: August 1, 2019
    Inventors: Zhuoxiao Cao, Yayuan Fu, Qiyue Hu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
  • Patent number: 10364234
    Abstract: Pyridinecarboxamide derivatives, preparation methods, and a pharmaceutical uses thereof are provided. In particular, pyridinecarboxamide derivatives represented by general formula (I), wherein the substituents of the formula (I) are defined in the specification are provided. Also provided are a preparation method for the pyridinecarboxamide derivatives of formula (I), a pharmaceutical composition containing the pyridinecarboxamide derivatives, and uses of the pyridinecarboxamide derivatives as therapeutic agents, especially as inhibitors of the Renal Outer Medullary Potassium channel (ROMK) and in the preparation of medicaments for treating and/or preventing hypertension and heart failure.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 30, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Qing Dong, Piaoyang Sun